Eligo raises $20M series A

On Sept. 26, microbiome company Eligo Bioscience S.A.S. (Paris, France) said it raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. CEO and Chairman Xavier Duportet told BioCentury the round, which included a $2 million award from France's Worldwide Innovation Challenge, also included €2 million in financing from Seventure in 2015. Eligo has raised a total of $24 million to date, which Duportet said includes equity and non-dilutive funding. Duportet declined to disclose total equity.

Eligo synthesizes biotherapeutics, which it calls eligobiotics, to target specific bacteria strains within the microbiome. The platform's first application is delivering CRISPR-Cas machinery into gut microbiome to selectively kill specific pathogenic bacteria based on their genetic signature...